- Title: Subtitle
- CMT AND NEUROGENIC DISEASE: P.339Preliminary phase 2 results for ACE-083, local muscle therapeutic, in patients with CMT1 and CMTX
- Creators
- M Shy - University of Iowa, Iowa City, USAD Herrmann - University of Rochester, Rochester, USAF Thomas - Hackensack Medical Center, Hackensack, USAC Quinn - University of Pennsylvania, Philadelphia, USAJ Statland - University of Kansas, Kansas City, USAD Walk - University of Minnesota, Minneaolis, USAN Johnson - University of Utah, Salt Lake City, USAS Subramony - University of Florida, Gainesville, USAC Karam - Oregon Health & Sciences Unive, Portland, USAT Mozaffar - University of California, Irvine, USAS D'Eon - Acceleron Pharma, Cambridge, USAB Miller - Acceleron Pharma, Cambridge, USAC Glasser - Acceleron Pharma, Cambridge, USAM Sherman - Acceleron Pharma, Cambridge, USAK Attie - Acceleron Pharma, Cambridge, USA
- Resource Type
- Abstract
- Publication Details
- Neuromuscular disorders : NMD, Vol.28, pp.S132-S133
- Publisher
- Elsevier B.V
- DOI
- 10.1016/j.nmd.2018.06.387
- ISSN
- 0960-8966
- eISSN
- 1873-2364
- Language
- English
- Date published
- 10/2018
- Academic Unit
- Molecular Physiology and Biophysics; Neurology; Iowa Neuroscience Institute; Stead Family Department of Pediatrics
- Record Identifier
- 9984071956802771
Abstract
CMT AND NEUROGENIC DISEASE: P.339Preliminary phase 2 results for ACE-083, local muscle therapeutic, in patients with CMT1 and CMTX
Neuromuscular disorders : NMD, Vol.28, pp.S132-S133
10/2018
DOI: 10.1016/j.nmd.2018.06.387
Details
Metrics
18 Record Views